Tag: AbbVie Inc (ABBV)
Prohost Letter #412 Part 3
Prohost Letter #412 Part 3 GLIOBLASTOMA - Is There Hope? Senator John McCain was diagnosed with a malignant brain tumor, glioblastoma – the most common and aggressive form of brain cancer. The cancer is so aggressive that most surgeries did...
Read More
August 3, 2017
0
New Breakthrough Immuno-Oncology Products
The Week in Review #7 A lot more happened in the past week regarding improving the treatment of cancer and of other devastating diseases. This issue contains discoveries that aim at improving breakthrough immuno-oncology treatment outcomes. Here are some of...
Read More
October 9, 2017
0
Tracing Large Pharmaceutical Companies' Choices
The Week in Review #8 Potential biotech winners inspired through COLLABORATION - When successful top-tier drug developing firms such as Amgen (AMGN) or Merck (MRK) sign strategic collaborating agreements with small development-stage biotech firms,... ...
Read More
October 16, 2017
0
Revisiting Biotech Companies We Highlighted
Prohost Letter #421 PRIVATE LESSONS - Stock prices of publicly-traded biotech companies oscillate for the same reasons other industries’ stock prices swing all day long. The fluctuations are the outcome of investors’ and daily traders’ unrelenting buying and selling... ...
Read More
May 25, 2018
0
The FDA approved Neurocrine’s & AbbVie’s Endometriosis drug, Orilissa. Neurocrine stock met & surpassed the Prohost 2018 target
AbbVie (NYSE: ABBV) , in cooperation with Neurocrine Biosciences (NBIX) , announced that the United States FDA approved Orilissa ™ (elagolix) under priority review for women with moderate to severe endometriosis pain. Orilissa represents the first FDA-approved oral treatment for...
Read More
July 25, 2018
0
Stories about research, clinical trials results and an FDA ruling
The Week in Review #26 IN THE BIOTECH WORLD - RESEARCH - IMPROVING CRISPR GENE EDITING The problem cited with gene editing is that the editing may stay switched on after it succeeded in reaching its goals. To prevent further...
Read More
July 9, 2018
0
Another Week of Outperformance
The Week in Review #16 More Exciting Rallies in Prohost Picks - The past week and for several week fascinating outperformances have been seen for many of the Prohost Portfolio stocks. We continue to articulate that the good news is...
Read More
January 16, 2018
0
Argenx's product, Efgartigimod, demonstrates positive results in primary immune thrombocytopenia
Phase 2 clinical trial data of argenx’s (ARGX) product Efgartigimod (ARGX-113) in adult patients with primary immune thrombocytopenia (ITP) showed a favorable safety and tolerability profile. The results also demonstrated that efgartigimod caused meaningful platelet count improvements across doses...
Read More
September 17, 2018
0
CytomX Therapeutics: A Noteworthy Expansion of Collaborative Agreement with BMY
Everybody knows Bristol-Myers Squibb (BMY) , but just a few may know anything about CytomX Therapeutics (CTMX ) , or about its Probody Program. CytomX is a small, develop-ment-stage firm that created platform known as the Probody Program, which leads...
Read More
March 23, 2017
0
Prohost Letter #407
Prohost Letter #407 AT A GLANCE - Firms Added to Prohost Portfolio PROHOST IS PICKING NEUROCRINE BIOSCIENCES On March 27, a few days before the FDA approves Neurocrine’s (NBIX) drug Ingrezza, (valbenazine) capsules for adults with tardive dyskinesia (TD),...
Read More
April 20, 2017
0
Search ProhostBiotech
Popular Links
23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)